Cassava Sciences President and CEO Remi Barbier is hitting back at The New York Times, calling out the venerable newspaper for an alleged one-sided article that he claims misrepresented the research of his company by only using sources who were critical of Cassava.

Ansa Biotechnologies, a California-based start-up focused on updating DNA synthesis technologies, is advancing toward the launch of a customizable DNA synthesis service, stemming from the development of a novel synthesis method.

Cellino Biotech announced a completed Series A financing of $80 million led by the impact investment arm of Bayer AG, Leaps by Bayer, 8VC, and Humboldt Fund and includes new investor Felicis Ventures.

Ceptur Therapeutics – based in Hillsborough, NJ, Philadelphia and Copenhagen – closed on a Series A financing round worth $75 million.

Is the life sciences industry a good bet right now? BioSpace put a poll in the field, which elicited mixed results. In order to get a clearer picture, BioSpace spoke to a few knowledgeable industry experts.  

BioSpace presented its NextGen Bio “Class of 2022,” a list of up-and-coming life sciences companies in North America that recently launched.

Seattle-based Mozart Therapeutics closed on a $55 million Series A financing round, led by seed financier ARCH Venture Partners along with Sofinnova Partners. Additional investors were Eli Lilly and Company, MRL Ventures Fund, an early-stage fund run by Merck & Co., Leaps by Bayer, Altitude Life Science Ventures, and Alexandria Venture Investments.

Four biotech companies announced Series A rounds: Vita Therapeutics, NuvoAir, Enveda Biosciences, and ImmuneID.

Biopharma companies Gennao Bio and Juno Diagnostics raised a combined $65 million in Series A funding rounds.

BioSpace takes a look at Series A financing rounds for several biotech companies: San Francisco-based Esker Therapeutics; England’s Mogrify Limited; Duke University spinout Isolere Bio; and Sunnyvale, California-based BridGene Biosciences.